Literature DB >> 22613583

Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repair.

Annabelle E Fenske1, Stephanie Glaesener, Carsten Bokemeyer, Juergen Thomale, Jochen Dahm-Daphi, Friedemann Honecker, Dorothee C Dartsch.   

Abstract

To identify factors involved in cisplatin (CDDP) resistance of germ cell tumours (GCTs), we exposed NTERA-2 cells, and the platinum-adapted subline NTERA-2R to CDDP and compared their response. While both cell lines showed comparable proliferation, NTERA-2R cells were clearly more resistant to the drug than the parental NTERA-2 cell line. Interestingly, the two lines showed identical extent of DNA adduct formation and elimination, indicating that neither changes in CDDP uptake, nor altered drug efflux, DNA binding, or repair caused the difference in resistance. Similarly, no difference occurred in the time-course of γH2AX formation, which was not linked to 53BP1 accumulation. In contrast, NTERA-2R cells showed a more pronounced dose-dependent S phase delay, a transient G(2)/M-block, and subsequent release into immediate cell death. We thus conclude that the enhanced resistance against CDDP is linked to reduced susceptibility to cell death rather than to an altered DNA adduct formation or adduct removal.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22613583     DOI: 10.1016/j.canlet.2012.05.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  RANKL regulates testicular cancer growth and Denosumab treatment has suppressive effects on GCNIS and advanced seminoma.

Authors:  Christine Hjorth Andreassen; Mette Lorenzen; John E Nielsen; Sam Kafai Yahyavi; Birgitte Grønkær Toft; Lars R Ingerslev; Christoffer Clemmensen; Lene Juel Rasmussen; Carsten Bokemeyer; Anders Juul; Anne Jørgensen; Martin Blomberg Jensen
Journal:  Br J Cancer       Date:  2022-04-13       Impact factor: 9.075

2.  Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells.

Authors:  Mirjam Gerwing; Christine Jacobsen; Sergey Dyshlovoy; Jessica Hauschild; Tina Rohlfing; Christoph Oing; Simone Venz; Jan Oldenburg; Karin Oechsle; Carsten Bokemeyer; Gunhild von Amsberg; Friedemann Honecker
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-16       Impact factor: 4.553

3.  Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours.

Authors:  J Mendoza; J Martínez; C Hernández; D Pérez-Montiel; C Castro; E Fabián-Morales; M Santibáñez; R González-Barrios; J Díaz-Chávez; M A Andonegui; N Reynoso; L F Oñate; M A Jiménez; M Núñez; R Dyer; L A Herrera
Journal:  Br J Cancer       Date:  2013-06-27       Impact factor: 7.640

4.  Platinum nanoparticles induce damage to DNA and inhibit DNA replication.

Authors:  Lukas Nejdl; Jiri Kudr; Amitava Moulick; Dagmar Hegerova; Branislav Ruttkay-Nedecky; Jaromir Gumulec; Kristyna Cihalova; Kristyna Smerkova; Simona Dostalova; Sona Krizkova; Marie Novotna; Pavel Kopel; Vojtech Adam
Journal:  PLoS One       Date:  2017-07-12       Impact factor: 3.240

5.  Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells.

Authors:  Silvia Schmidtova; Katarina Kalavska; Katarina Gercakova; Zuzana Cierna; Svetlana Miklikova; Bozena Smolkova; Verona Buocikova; Viera Miskovska; Erika Durinikova; Monika Burikova; Michal Chovanec; Miroslava Matuskova; Michal Mego; Lucia Kucerova
Journal:  Cancers (Basel)       Date:  2019-08-22       Impact factor: 6.639

6.  Novel sequential therapy with metformin enhances the effects of cisplatin in testicular germ cell tumours via YAP1 signalling.

Authors:  Kancheng He; Zitaiyu Li; Kun Ye; Yihong Zhou; Minbo Yan; Hao Qi; Huating Hu; Yingbo Dai; Yuxin Tang
Journal:  Cancer Cell Int       Date:  2022-03-09       Impact factor: 5.722

7.  Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry.

Authors:  A Fichtner; H Bohnenberger; S Kueffer; D Nettersheim; F Bremmer; O Elakad; A Richter; C Lenz; C Oing; P Ströbel
Journal:  World J Urol       Date:  2022-01-27       Impact factor: 4.226

Review 8.  The rediscovery of platinum-based cancer therapy.

Authors:  Sven Rottenberg; Carmen Disler; Paola Perego
Journal:  Nat Rev Cancer       Date:  2020-10-30       Impact factor: 60.716

9.  CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms.

Authors:  Margaretha A Skowron; Marieke Vermeulen; Anna Winkelhausen; Teresa K Becker; Felix Bremmer; Patrick Petzsch; Stefan Schönberger; Gabriele Calaminus; Karl Köhrer; Peter Albers; Daniel Nettersheim
Journal:  Br J Cancer       Date:  2020-05-18       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.